BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31155442)

  • 21. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P; Gaston L; Borkowska A; Stacchiotti S; Gelderblom H; Baldi GG; Palmerini E; Casali P; Gronchi A; Parry M; Campanacci DA; Scoccianti G; Wagrodzki M; Ferrari S; Dijkstra S; Pieńkowski A; Grimer R
    Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risks and benefits of combining denosumab and surgery in giant cell tumor of bone-a case series.
    Müller DA; Beltrami G; Scoccianti G; Campanacci DA; Franchi A; Capanna R
    World J Surg Oncol; 2016 Nov; 14(1):281. PubMed ID: 27809843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
    Puri A; Gulia A; Hegde P; Verma V; Rekhi B
    Bone Joint J; 2019 Feb; 101-B(2):170-177. PubMed ID: 30700112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
    Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
    Medellin MR; Fujiwara T; Tillman RM; Jeys LM; Gregory J; Stevenson JD; Parry M; Abudu A
    Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS; Hindiskere S; Doddarangappa S; Pal U
    Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
    Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study.
    Urakawa H; Yonemoto T; Matsumoto S; Takagi T; Asanuma K; Watanuki M; Takemoto A; Naka N; Matsumoto Y; Kawai A; Kunisada T; Kubo T; Emori M; Hiraga H; Hatano H; Tsukushi S; Nishida Y; Akisue T; Morii T; Takahashi M; Nagano A; Yoshikawa H; Sato K; Kawano M; Hiraoka K; Tanaka K; Iwamoto Y; Ozaki T
    World J Surg Oncol; 2018 Aug; 16(1):160. PubMed ID: 30089488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use.
    Fujihara N; Hamada S; Yoshida M; Tsukushi S
    BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34764115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N; Saito M; Kobayashi E; Morii T; Kikuta K; Watanabe I; Anazawa U; Takeuchi K; Suzuki Y; Susa M; Nishimoto K; Ishii R; Miyazaki N; Mrioka H; Kawai A; Horiuchi K; Nakayama R
    Ann Surg Oncol; 2022 Jun; 29(6):3992-4000. PubMed ID: 35175454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab Does Not Decrease Local Recurrence in Giant Cell Tumor of Bone Treated With En Bloc Resection.
    Tsukamoto S; Mavrogenis AF; Tanaka Y; Kido A; Kawaguchi M; Errani C
    Orthopedics; 2021; 44(6):326-332. PubMed ID: 34618637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
    Urakawa H; Mizusawa J; Tanaka K; Eba J; Hiraga H; Kawai A; Nishida Y; Hosaka M; Iwamoto Y; Fukuda H; Ozaki T
    Jpn J Clin Oncol; 2019 Apr; 49(4):379-382. PubMed ID: 30796832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of intraoperative magnetic resonance imaging for giant cell tumor of bone after denosumab treatment: a pilot study.
    Furuta T; Kubo T; Sakuda T; Saito T; Kurisu K; Muragaki Y; Adachi N
    Acta Radiol; 2022 Feb; 63(2):176-181. PubMed ID: 33517664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
    von Borstel D; A Taguibao R; A Strle N; E Burns J
    Skeletal Radiol; 2017 Apr; 46(4):571-578. PubMed ID: 28188337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E; Seeger LL; Gambarotti M; Righi A; Reichardt P; Bukata S; Blay JY; Dai T; Jandial D; Picci P
    BMC Cancer; 2021 Jan; 21(1):89. PubMed ID: 33482769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Giant Cell Tumor of Bone of the First Rib Successfully Treated with Combined Preoperative Denosumab Therapy and Surgery via a Transmanubrial Approach.
    Matsunobu T; Maekawa A; Nabeshima A; Sakamoto A; Tamura K; Odate S; Iwamoto Y
    Am J Case Rep; 2021 Jun; 22():e931796. PubMed ID: 34059614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
    Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
    Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
    Tang Q; Lu J; Zhu X; Song G; Wu H; Xu H; Wang A; Wang J
    Eur Spine J; 2023 Dec; 32(12):4297-4305. PubMed ID: 37318598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new computerized tomography classification to evaluate response to Denosumab in giant cell tumors in the extremities.
    Campanacci L; Sambri A; Medellin MR; Cimatti P; Errani C; Donati DM
    Acta Orthop Traumatol Turc; 2019 Sep; 53(5):376-380. PubMed ID: 31253385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.